Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSRIT4)

Drug Name

Lenzilumab Drug Info

Synonyms

lenzilumab; GTPL8935; KB003; KB-003

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[1]
Chronic myelogenous leukaemia	2A20.0	Phase 1	[2]

Therapeutic Class

Antiviral Agents

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Granulocyte-macrophage colony-stimulating factor (CSF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talimogene Laherparepvec	DMKBW5C	Melanoma	2C30	Approved	[4]
JX-594	DM5WCV4	Hepatocellular carcinoma	2C12.02	Phase 3	[5]
Mavrilimumab	DMMVFRC	Rheumatoid arthritis	FA20	Phase 2	[6]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[2]
KB002/003	DM60G5O	Rheumatoid arthritis	FA20	Phase 2	[7]
GSK3196165	DMEXKF4	Rheumatoid arthritis	FA20	Phase 2	[6]
KB-003	DM74KIM	Severe asthma	CA23	Phase 2	[8]
MT203	DM7I0MT	Plaque psoriasis	EA90.0	Phase 2	[9]
MORAb-022	DMM7TBO	Autoimmune diabetes	5A10	Phase 1	[10]
Autologous melanoma cell vaccine	DMARYFK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting HUMAN colony-stimulating factor (GM-CSF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Otilimab	DM1AQLW	Rheumatoid arthritis	FA20	Phase 2 Trial	[3]
TJ003234	DM0VXIM	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2 Trial	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN colony-stimulating factor (GM-CSF)	TTPZGYX	CSF2_HUMAN	Inhibitor	[3]
Granulocyte-macrophage colony-stimulating factor (CSF2)	TTNYZG2	CSF2_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04351152) Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
9	GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
10	Clinical pipeline report, company report or official report of Morphotek.